|
Malignant tumor of colon
|
0.020 |
Biomarker
|
disease |
BEFREE |
We used Colo320 (ATCC, CCL-220), Colo741 (ECACC, 93052621) and HCT116 (ATCC, CCL-247) colon cancer cell lines.
|
31390540 |
2019 |
|
Heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
We aimed to evaluate whether the combination of circulating biomarkers of CCL [the carboxy-terminal telopeptide of collagen type I to matrix metalloproteinase-1 ratio (CITP : MMP-1)] and CD [the carboxy-terminal propeptide of procollagen type I (PICP)] identifies myocardial fibrosis phenotypes with distinct clinical outcome in hypertensive patients with heart failure.
|
28253222 |
2017 |
|
Heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
A combination of circulating biomarkers associated with excessive myocardial collagen type-I cross-linking or CCL+ (i.e., decreased carboxy-terminal telopeptide of collagen type-I to matrix metalloproteinase-1 ratio) and with excessive myocardial collagen type-I deposition or CD+ (i.e., increased carboxy-terminal propeptide of procollagen type-I) has been described in heart failure (HF) patients and associates with poor outcomes.
|
30922470 |
2019 |
|
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
The maximum tolerated dose by IT injection of >92 μg (Human equivalent dose [HED] of >0.3 mg/kg) in CCL-247 tumor xenograft-bearing athymic mice was ∼10-fold higher than the extrapolated IC(50) of 9 μg (HED of 0.03 mg/kg).
|
21612405 |
2011 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Afatinib also inhibited the growth of other tumour cell lines with IC50 values which ranged from 0.33 µM (CCL-221) to 1.62 µM (HCT-116).
|
21617858 |
2011 |
|
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We used Colo320 (ATCC, CCL-220), Colo741 (ECACC, 93052621) and HCT116 (ATCC, CCL-247) colon cancer cell lines.
|
31390540 |
2019 |
|
Colon Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
In our study, we aimed to investigate the effect of juglone on CCL-228-SW 480 colon carcinoma cell line in monolayer and spheroid culture medium.
|
30880757 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Secondary thresholds of Gleason ≥4 + 3, Ahmed/UCL1 (Gleason ≥4 + 3 or maximum cancer core length [CCL] ≥6 or total CCL≥6) and Ahmed/UCL2 (Gleason ≥3 + 4 or maximum CCL ≥4 or total CCL ≥6) were also used.
|
31599113 |
2020 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
CCL18 is a member of CCL chemokines and is frequently overexpressed in cancer.
|
26242263 |
2016 |
|
Aortic Valve Stenosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Myocardial and serum miR-19b were inversely correlated (p < 0.05) with LOX, CCL and LV stiffness in AS patients.
|
28091585 |
2017 |
|
Asthma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
A CCL chemokine-derived peptide (CDIP-2) exerts anti-inflammatory activity via CCR1, CCR2 and CCR3 chemokine receptors: Implications as a potential therapeutic treatment of asthma.
|
24560857 |
2014 |
|
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
The purpose of this study was to investigate whether the CCL+CD+ combination of biomarkers associates with atrial fibrillation (AF).
|
30922470 |
2019 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Transfection with the bi-shSTMN1-encoding expression plasmid (pbi-shSTMN1) markedly reduced CCL-247 human colorectal cancer and SK-Mel-28 melanoma cell growth in vitro (Rao et al., 2010 ).
|
21612405 |
2011 |
|
Eosinophilia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, blockage of CCL-6 with a specific neutralizing antibody, restored the reconstitution ability of HSCs while exacerbating eosinophilia airway inflammation in OVA-challenged mice.
|
29327730 |
2018 |
|
Immunologic Deficiency Syndromes
|
0.010 |
Biomarker
|
group |
BEFREE |
Polyfunctional analysis of Vδ1 T cells from HIV-positive individuals revealed a lower frequency of CD107A<sup>+</sup> CCL-4<sup>+</sup> Vδ1 T-cell subsets than healthy donors that persists after therapy.
|
31206171 |
2019 |
|
Icterus
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Using commercially available antibodies against BAAT and CCL, we immunostained liver from an infant with jaundice, deficiency of amidated bile acids, and transcription-terminating mutation in BAAT.CCL was normally expressed.BAAT expression was not detected.
|
22783059 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
mAbs: Monoclonal antibodies; EF2: elongation factor 2; ITs: Immunotoxins; DT: Diphtheria toxin; PE: Pseudomonas exotoxin; dgA: de-glycosylated A-chain of ricin; rGel: recombinant de-glycosylated form of gelonin; NKC: natural killer cells; HTR: human transferrin receptor; EGF: epidermal growth factor; GM-CSF: granulocyte-macrophage colony-stimulating factor; DAB389: truncated Diphtheria toxin; B-CCL: B-cell chronic lymphocytic leukemia; RCC: renal cell carcinoma; GVHD: Graft-versus-host disease; EGFR: epidermal growth factor receptor; AML: acute myeloid leukemia; Fab: fragment antigen-binding; dsFv: disulfide-stabilized fragment variable; scFv: single-chain fragment variable; B-ALL: B-lineage Acute Lymphoblastic Leukemia; Fv: fragment variable; HCL: hairy cell leukemia; IL-2R: Interleukin-2 receptor; CR: complete response; CLL: chronic lymphocytic leukemia; ATL: adult T-cell leukemia; DARPins: designed Ankyrin repeat proteins; pmol: picomolar; HAMA: human-anti mouse antibody.
|
28282218 |
2017 |
|
Chronic Obstructive Airway Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data demonstrate that sputum macrophages in COPD show induction of a specific set of CCL chemokines, which is distinct from what can be induced by LPS.
|
21327296 |
2011 |
|
Lupus Erythematosus, Systemic
|
0.010 |
Biomarker
|
disease |
BEFREE |
CCL genes in multiple sclerosis and systemic lupus erythematosus.
|
18602166 |
2008 |
|
Multiple Sclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
CCL genes in multiple sclerosis and systemic lupus erythematosus.
|
18602166 |
2008 |
|
Neuroblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We previously reported that coated cationic liposomes (CCL) targeted with a monoclonal antibody against the disialoganglioside (GD(2)) and containing c-myb antisense oligodeoxynucleotides (asODNs) resulted in a selective inhibition of the proliferation of GD(2)-positive neuroblastoma cells in vitro.
|
14555535 |
2003 |
|
Otitis Media
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Many CCL genes showed increased expression levels during acute OM, with CCL3 being the most upregulated, at levels 600-fold higher than the baseline.
|
28847849 |
2017 |
|
Tuberculosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
These compounds had their activity evaluated toward a Mycobacterium tuberculosis strain (ATCC 27294) and cytotoxicity against fibroblast MRC-5 cells (ATCC CCL-171).
|
29679451 |
2018 |
|
Renal fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study aimed to characterize the association between intrinsic renal cells (tubular epithelial cells and mesangial cells) and Th22 cells in immune regulation of infection-related IgAN and to elucidate the impact of Th22 lymphocytosis; the proinflammatory cytokines IL-1, IL-6, and TNF-α; and CCL chemokines on kidney fibrosis.
|
28875388 |
2018 |
|
Chronic heart failure
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, decreased miR-19b may be involved in myocardial LOX up-regulation and excessive CCL, and consequently increased LV stiffness in AS patients, namely in those with HF.
|
28091585 |
2017 |